- Conditions
- Hypotension, Orthostatic
- Interventions
- midodrine hydrochloride (ProAmatine®)
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 3
- States / cities
- St. Petersburg, Florida • Upland, Pennsylvania • San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 448
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Ethanol, Glucagon
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hypertension
- Interventions
- Metoprolol succinate, Nebivolol, Non-invasive measurement of Cardiac Output (CO), Endothelial cell collection, Microvascular perfusion assessment using Definity
- Drug · Procedure
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Alcohol Dependence
- Interventions
- D-Cycloserine PO and Glycine IV, Placebo D-Cycloserine PO and placebo Glycine IV, Placebo D-Cycloserine PO and Glycine IV, D-Cycloserine PO and placebo Glycine IV
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1997 – 2008
- U.S. locations
- 1
- States / cities
- West Haven, Connecticut
- Conditions
- Malignant Neoplam, Advanced Solid Tumors
- Interventions
- MK-2010, Pembrolizumab, 5-Fluorouracil, Leucovorin or Levoleucovorin, Oxaliplatin, Belzutifan, Gemcitabine, Cisplatin, Carboplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed, Epinephrine
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 4
- States / cities
- Belleville, New Jersey • East Brunswick, New Jersey • Maumee, Ohio + 1 more
- Conditions
- Malaria, Malaria, Cerebral
- Interventions
- Intravenous Artesunate, Placebo
- Drug
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hypotension
- Interventions
- Phenylephrine
- Drug
- Lead sponsor
- West-Ward Pharmaceutical
- Industry
- Eligibility
- 12 Years to 16 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2024
- U.S. locations
- 10
- States / cities
- Wilmington, Delaware • Washington D.C., District of Columbia • Miami, Florida + 7 more
- Conditions
- Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging
- Interventions
- Elranatamab, Lenalidomide, Plerixafor, Melphalan, Busulfan, G-CSF, Stem cell transplant
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hematologic Neoplasms
- Interventions
- donor lymphocyte infusion, Cyclophosphamide, Busulfan, Mycophenolate mofetil, Fludarabine, Sirolimus
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years to 120 Years
- Enrollment
- 430 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Myeloma, Lymphoma
- Interventions
- Busulfan, Fludarabine
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 16 Years to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Immune System
- Interventions
- Endotoxin, Lipopolysaccharide, LPS, Endotoxin, Epinephrine
- Biological
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Leukemia
- Interventions
- cyclophosphamide, cyclosporine, etoposide, methotrexate, allogeneic bone marrow transplantation, Total Body Irradiation, Busulfan, Mesna, Radiation
- Drug · Procedure · Radiation
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2001
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • San Diego, California • Jacksonville, Florida + 11 more
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chemotherapy-Related Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Langerhans Cell Histiocytosis, Minimal Residual Disease, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Myelodysplastic Syndrome, Small Lymphocytic Lymphoma, Therapy-Related Myelodysplastic Syndrome
- Interventions
- Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide, Filgrastim-sndz, Fludarabine, Melphalan, Mycophenolate Mofetil, Rituximab, Tacrolimus, Total-Body Irradiation, Umbilical Cord Blood Transplantation
- Biological · Drug · Radiation + 1 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- Carfilzomib, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 59
- States / cities
- Bakersfield, California • Burbank, California • Fountain Valley, California + 26 more
- Conditions
- Alcohol Use Disorder
- Interventions
- Ethanol, Saline
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 21 Years to 45 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Alcohol Drinking
- Interventions
- Alcohol (Oral), Alcohol (IV), Alcohol (Ethanol)
- Drug
- Lead sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- NIH
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unusual Cancers of Childhood
- Interventions
- anti-thymocyte globulin, filgrastim, busulfan, carmustine, cyclophosphamide, cyclosporine, cytarabine, etoposide, fludarabine phosphate, melphalan, methotrexate, methylprednisolone, mycophenolate mofetil, tacrolimus, peripheral blood stem cell transplantation, umbilical cord blood transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Alcohol Dependence
- Interventions
- Prometa Treatment Program
- Drug
- Lead sponsor
- Institute of Addiction Medicine
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
- Interventions
- Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Gemcitabine Hydrochloride, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Rituximab, Tacrolimus
- Procedure · Biological · Drug + 1 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Mucopolysaccharidosis I, Mucopolysaccharidosis VI, Mannosidosis, Mucolipidosis Type II (I-cell Disease)
- Interventions
- Stem Cell Transplant, Busulfan, Cyclophosphamide, ATG
- Procedure · Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Not listed
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2010
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary Myelofibrosis
- Interventions
- Ruxolitinib, Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Computed Tomography, Cyclophosphamide, Echocardiography Test, Fludarabine, JAK Inhibitor, Melphalan, Methotrexate, Tacrolimus, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Drug · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Alcohol Abuse
- Interventions
- Alcoholic Beverage, Non-Alcoholic Beverage, Ethanol
- Other · Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 21 Years to 45 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Melanoma (Skin)
- Interventions
- ADI-PEG-20, Pharmacology Studies
- Biological · Other
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Asthma
- Interventions
- Budesonide / formoterol fumarate (SYMBICORT), Budesonide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 311 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 57
- States / cities
- Pell City, Alabama • Bentonville, Arkansas • Hot Springs, Arkansas + 54 more